Scope and Claims Review for US Drug Patent 10,052,334 (3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]-propionic methyl ester), plus US Patent Landscape and Generic/Par IV Risk
US Patent 10,052,334 is directed to methods of intravenous procedural sedation (including induction and maintenance) using a specific active: 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]-propionic methyl ester (Formula I) or pharmaceutically acceptable salts, with explicit dose-governance constraints that (a) do not depend on body weight, and (b) are administered in short injection windows with bounded top-up cadence and maximum number of supplemental doses. The practical claim coverage is narrow-to-moderate by design: it targets a very specific dosing paradigm rather than merely the molecule.
How broad is the invention in US Patent 10,052,334?
Claim 1 is the independent claim and drives the enforceable “shape” of the patent:
What the patent covers (core elements)
- Induction and maintenance of sedation for a subject undergoing a procedure
- Intravenous administration of:
- an initial dose, and
- one or more supplemental doses
- The composition includes:
- Formula (I) (the defined imidazo[1,2-a][1,4]benzodiazepine derivative with bromo and 2-pyridinyl substituents) or a pharmaceutically acceptable salt
- Dose does not depend on body weight
- The initial and supplemental dosing are part of a structured sedation regimen (expanded by dependent claims)
What the patent does not cover (by omission)
- Oral or non-IV administration is not claimed in the provided text except via dependent claim language specifying intravenous.
- Weight-based titration regimens are excluded by the “does not depend on body weight” limitation.
- Sedation regimens not aimed at induction/maintenance (outside the claim framing) are not directly captured.
What are the exact dosing and administration limitations that define claim scope?
A significant share of the real-world infringement risk turns on several “hard” dosing constraints.
Body-weight independence
- Claim 1 limitation: initial dose and supplemental doses “do not depend on the body weight of the subject.”
- This is the single strongest gating limitation versus many clinical titration standards that adjust dose by patient characteristics.
Time-on-injection constraint
- Claim 9: each initial and supplemental dose is administered over one minute or less.
This narrows coverage against slow IV infusion protocols.
Top-up structure
- Claim 17: number of top-up supplemental doses is 6 or less.
- Claim 18: top-up doses are administered no sooner than 2 minutes after the initial dose.
This narrows against regimens that stack boluses quickly (under 2 minutes) or use larger numbers of top-ups.
Opioid co-administration timing
- Claim 3: opioid dose prior to IV administration of Formula (I)
- Claim 4: opioid is fentanyl
- Claim 20: opioid is administered no earlier than 10 minutes prior to the initial dose
This is a second strong gating limitation. Many endoscopy protocols vary opioid timing; if fentanyl is given earlier than 10 minutes, the literal “no earlier than” window can be avoided.
Dose range limitations
Multiple dependent claims set quantitative ranges for the initial dose when claimed:
- Claim 21: initial dose 2 mg to 10 mg
- Claim 22: 3 mg to 10 mg
- Claim 23: 3 mg to 9 mg
- Claim 24: 5 mg to 8 mg
- Claim 25: 2 mg to 10 mg (duplicative range coverage in your excerpt)
- Claims 26-28: nested subranges
- Claim 29: initial dose about 5 mg
These ranges create multiple “sub-claims” that can independently read on commercial dosing if any of the ranges align.
Dose formulation: saline solution
- Claim 19: administered in the form of a saline solution
- (Claim 41 repeats this for the procedural sedation embodiment)
This is formulation-administration specific. If a product is marketed/used in another vehicle (even with the same active and dose timing), the literal fit can change.
What sedation types and procedures are explicitly captured?
Sedation spectrum
- Claim 10: sedation is selected from:
- mild sedation
- moderate sedation
- deep sedation
- procedural sedation
- analgosedation
- general anesthesia
- Claims 11-15: narrow subsets and ranges:
- deep sedation and general anesthesia singled out (Claims 12-14)
- sedation ranges “from mild to general” (Claim 15)
- “from mild to deep” (Claim 16)
This means the patent is not confined to one sedation depth.
Procedures
- Claim 5: diagnostic procedure
- Claim 6: colonoscopy
- Claim 7: upper GI endoscopy
- Claim 8: therapeutic procedure
- Claim 42: endoscopy (generic bucket)
- Claims 43-45: endoscopy during administration and specifically colonoscopy and upper GI endoscopy
The inclusion of both “endoscopy” and specific endoscopy types (colonoscopy, upper GI) makes the patent commercially targeted for gastroenterology settings.
How is the patent’s claim structure likely to be attacked or designed around?
Key literal-infringement “design-around” levers
- Restore body-weight dependence in dosing
If a competitor uses a dosing scheme where initial dose or top-up dosing depends on body weight, it can break the “does not depend” limitation.
- Use slower injection/infusion (>1 minute)
Claim 9 uses a bright-line timeframe. Infusion protocols over 1 minute can avoid literal coverage.
- Change top-up cadence (<2 minutes after initial) or increase top-up count (>6)
Claim 18 and Claim 17 are cadence and count constraints.
- Alter opioid timing relative to Formula (I)
If fentanyl is given earlier than 10 minutes prior, it may avoid Claim 20’s timing constraint.
- Change vehicle from saline solution
If formulation/administration uses a different diluent/vehicle, Claim 19/41 becomes a potential escape route.
Non-literality risks
Even with these levers, a doctrine-of-equivalents argument can be pursued by a patentee if the competitor’s regimen is functionally similar. But the patent text, as provided, shows multiple narrow bright-line limitations, which typically increase design-around success.
What does the claim text imply about the underlying product profile?
Because the patent claims a specific molecule plus structured, IV-only sedation protocols with weight independence, the commercial product strategy likely centers on:
- a ready-to-administer IV formulation (saline solution per claims),
- a standardized mg dose (ranges and “about 5 mg”),
- a bolus-like administration pattern (≤1 minute),
- an endoscopy workflow including opioid co-administration (fentanyl) timed to typical sedation workflows.
This is not a claim to the molecule alone. It is a claim to a usable sedation regimen.
How many independent claim “pressure points” exist in the claim set you provided?
From the excerpt, the claim set includes one main independent claim (Claim 1) and a second independent claim (Claim 30) focused on procedural sedation:
- Claim 1: induction and maintenance in a procedure context
- Claim 30: procedural sedation method as a separate independent claim
Even if one independent embodiment is avoided, the other can remain relevant if the competitor still uses:
- IV administration
- formula I
- dose not body-weight dependent
- the procedural sedation framing
Dependent claims then stack procedural specificity (endoscopy, colonoscopy, upper GI endoscopy), timing (≤1 minute, fentanyl timing), and dosing windows.
What is the practical “infringement map” by scenario?
Scenario A: Endoscopy sedation with weight-based dosing
- Likely avoids Claim 1 and Claim 30 due to the “does not depend on body weight” requirement.
Scenario B: Endoscopy sedation with fixed mg dosing, but slow administration
- Likely avoids Claim 9 and Claim 40 if doses are given over more than 1 minute.
Scenario C: Fixed-dose bolus with ≤1 minute injection, standardized top-ups
- Higher risk for infringement if:
- top-ups occur no sooner than 2 minutes,
- ≤6 top-ups,
- saline vehicle is used,
- initial dose falls within one of the mg bands claimed.
Scenario D: Fixed-dose protocol with fentanyl, but fentanyl timed earlier
- Potentially avoids Claim 20 if fentanyl is given earlier than 10 minutes prior.
Scenario E: Different vehicle than saline
- Potential avoidance of Claim 19/41 if administration is not in saline solution.
What is the likely patent estate strategy around 10,052,334 (scope beyond this patent)?
Even without additional patent numbers in the prompt, the claim design indicates a typical estate pattern:
- Base compound patents (coverage of Formula I and salts)
- Method-of-use patents (sedation protocols)
- Formulation/administration patents (diluent, concentration, preparation)
- Dose-regimen patents (fixed dose, timing, top-up cadence)
US 10,052,334 appears to sit firmly in the method-of-use / dosing regimen tier.
What generic entry risks exist if a Paragraph IV challenge targets this method patent?
The main risk profile is not whether a generic can sell the active ingredient, but whether it can use or induce the claimed regimen.
If a generic sells Formula I IV drug
- The generic may be non-infringing if it avoids label instructions or practices that match:
- weight-independent dosing,
- ≤1 minute administration,
- top-up timing and maximum count,
- fentanyl timing,
- saline solution vehicle.
Risk increases if the label and REMS training align with the claimed regimen
- If the generic’s label (and commercial practice) instructs use in an endoscopy sedation workflow matching Claims 1/30 and dependent claims, it raises inducement/contributory infringement exposure.
Practical leverage
Method-of-use patents often produce:
- litigation focused on label language and clinical instructions,
- settlement agreements that limit labeling or require carve-outs.
Key Takeaways
- US 10,052,334 claims IV sedation induction/maintenance and procedural sedation using Formula (I) or salts.
- The patent scope is defined by multiple bright-line regimen constraints:
- fixed-dose not dependent on body weight
- IV administration ≤1 minute
- top-up timing ≥2 minutes and ≤6 top-ups
- fentanyl timing ≥10 minutes prior (when opioid + fentanyl is used)
- initial dose ranges including about 5 mg
- saline solution administration
- It is tightly directed to endoscopy settings, including colonoscopy and upper GI endoscopy, and spans sedation depths from mild to general anesthesia.
- Design-around is most feasible by changing body-weight dependency, administration time, top-up cadence/count, opioid timing, and vehicle.
FAQs
1) Does US 10,052,334 protect the molecule itself or only sedation methods?
It protects methods of sedation using the defined Formula (I) composition; the claim as provided is not a compound-only claim.
2) What is the most effective single design-around for this patent?
Changing the protocol so that dosing depends on body weight can defeat the foundational limitation of Claims 1 and 30.
3) Can a competitor avoid the patent by giving IV sedation slower than 1 minute?
Yes. Claims 9 and 40 include a ≤1 minute dosing window for initial and supplemental doses.
4) How do the fentanyl timing limitations affect clinical protocols?
If fentanyl is administered earlier than 10 minutes before Formula (I), Claim 20’s “no earlier than” limitation may not be met when following the opioid+fentanyl embodiment.
5) Are endoscopy procedures like colonoscopy explicitly covered?
Yes. The claims explicitly include colonoscopy and upper GI endoscopy, plus broader “endoscopy” categories.
References (APA)
- US Patent 10,052,334 (claims and text provided in the prompt).
